Who is sponsoring NCT00285012?

NCT00285012 is sponsored by Pfizer.

What condition does NCT00285012 study?

NCT00285012 studies Smoking Cessation.

What drugs are being tested in NCT00285012?

Interventions: placebo, Varenicline Tartarate.

What is the status of NCT00285012?

NCT00285012 is currently COMPLETED.

Last reviewed 2010-04-15 · How we verify

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease

NCT00285012 Phase 3 COMPLETED Results posted

This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.

Details

Lead sponsor	Pfizer
Phase	Phase 3
Status	COMPLETED
Enrolment	504
Start date	2006-05
Completion	2009-04

Conditions

Smoking Cessation

Interventions

placebo
Varenicline Tartarate

Primary outcomes

Number of Subjects With Four Week Continuous Quit Rate (CQR) — Week 9 through Week 12
Number of subjects who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory \[NUI\]) and with end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm) for weeks 9 through 12 (inclusive).

Countries

United States, France, Italy, Spain